GlassScriptPhysician profile
Ann M Bute
NPI 1801176987
$4,152.19
in general payments reported to CMS, 2019-2025
46 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $297 · 2023: $1,005 · 2024: $1,124 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.73 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $466.35 | 2022-2025 | |
| Seagen INC. | $263.51 | 2021-2025 | Padcev, Adcetris, Tivdak |
| Abbvie INC. | $225.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.54 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Gilead Sciences, INC. | $198.77 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $197.00 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Janssen Biotech, INC. | $183.89 | 2021-2025 | Rybrevant, Darzalex, Erleada |
| Pharmacyclics LLC, An Abbvie Company | $149.59 | 2022-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $148.51 | 2023-2025 | Keytruda, Welireg, Lenvima |
| Pfizer INC. | $139.47 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $136.81 | 2022-2025 | Libtayo |
| Daiichi Sankyo INC. | $131.79 | 2021-2025 | Enhertu, Datroway |
| Incyte Corporation | $124.98 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $113.99 | 2022-2025 | Opdivo, Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $110.76 | 2022-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $105.09 | 2021-2025 | |
| Genzyme Corporation | $103.81 | 2021-2025 | |
| Astellas Pharma US INC | $99.25 | 2024-2025 | Vyloy, Xtandi, Padcev |
| Lilly USA, LLC | $83.45 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Servier Pharmaceuticals LLC | $65.82 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.96 | 2023-2024 | Fruzaqla, Ninlaro |
| Kite Pharma, INC. | $55.26 | 2024-2025 | Yescarta |
| Beone Medicines USA, INC. | $55.12 | 2025 | Tevimbra |
| Deciphera Pharmaceuticals INC. | $52.38 | 2021-2024 | Qinlock |
| G1 Therapeutics, INC. | $50.17 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $49.93 | 2024-2025 | Monoferric, Cosela |
| Myovant Sciences INC. | $47.32 | 2021 | |
| Jazz Pharmaceuticals INC. | $44.61 | 2022-2025 | |
| Sobi, INC | $41.70 | 2024-2025 | |
| Geron Corporation | $41.33 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $40.42 | 2024 | |
| Puma Biotechnology, INC. | $40.14 | 2023-2025 | |
| Mirati Therapeutics, INC. | $38.53 | 2024 | Krazati |
| Sumitomo Pharma America, INC. | $36.24 | 2023-2024 | Orgovyx |
| Taiho Oncology, INC. | $30.92 | 2024-2025 | |
| Genmab U.S., INC. | $30.52 | 2023-2025 | Epkinly |
| Tersera Therapeutics LLC | $26.04 | 2023 | Zoladex |
| Corcept Therapeutics | $20.75 | 2025 | Korlym |
| Legend Biotech USA INC. | $19.40 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.27 | 2022 | |
| Stemline Therapeutics INC. | $19.23 | 2025 | Orserdu |
| Amgen INC. | $16.76 | 2023 | Lumakras |
| Blueprint Medicines Corporation | $14.36 | 2024 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $13.64 | 2021 | |
| Dova Pharmaceuticals | $12.83 | 2021 | |
| Rigel Pharmaceuticals, INC. | $11.88 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Bute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.